دورية أكاديمية
Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study.
| العنوان: | Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study. |
|---|---|
| المؤلفون: | Eijkelboom AH; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.; Department of Health Technology and Services Research, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, The Netherlands., de Munck L; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands., Menke-van der Houven van Oordt CW; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC Location VUMC, Amsterdam, The Netherlands., Broeders MJM; Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.; Dutch Expert Centre for Screening, Nijmegen, The Netherlands., van den Bongard DHJG; Department of Radiation Oncology, Amsterdam UMC, Amsterdam, The Netherlands., Strobbe LJA; Department of Surgical Oncology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Mureau MAM; Department of Plastic and Reconstructive Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Lobbes MBI; Department of Medical Imaging, Zuyderland Medical Center Sittard-Geleen, Geleen, The Netherlands.; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.; School for Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands., Westenend PJ; Laboratory of Pathology, Dordrecht, The Netherlands., Koppert LB; Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands., Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Siemerink EJM; Department of Internal Medicine, Ziekenhuis Groep Twente, Hengelo, The Netherlands., Wesseling J; Division of Diagnostic Oncology and Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., Verkooijen HM; Division of Imaging and Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands., Vrancken Peeters MTFD; Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.; Department of Surgery, Amsterdam UMC, Amsterdam, The Netherlands., Smidt ML; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, School for Oncology and Developmental Biology (GROW), Maastricht University Medical Centre, Maastricht, The Netherlands., Siesling S; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. s.siesling@utwente.nl.; Department of Health Technology and Services Research, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, The Netherlands. s.siesling@utwente.nl. |
| مؤلفون مشاركون: | NABON-COVID-19 Consortium, COVID and Cancer Care-NL Consortium |
| المصدر: | Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Jan; Vol. 197 (1), pp. 161-175. Date of Electronic Publication: 2022 Nov 05. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Dordrecht : Kluwer Academic Original Publication: The Hague ; Boston : M. Nijhoff, c1981- |
| مواضيع طبية MeSH: | Breast Neoplasms*/therapy , Breast Neoplasms*/drug therapy , COVID-19*/epidemiology, Humans ; Female ; Pandemics ; Communicable Disease Control ; Registries |
| مستخلص: | Purpose: We aimed to compare (1) treatments and time intervals between treatments of breast cancer patients diagnosed during and before the COVID-19 pandemic, and (2) the number of treatments started during and before the pandemic. Methods: Women were selected from the Netherlands Cancer Registry. For aim one, odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the treatment of women diagnosed within four periods of 2020: pre-COVID (weeks 1-8), transition (weeks 9-12), lockdown (weeks 13-17), and care restart (weeks 18-26), with data from 2018/2019 as reference. Wilcoxon rank-sums test was used to compare treatment intervals, using a two-sided p-value < 0.05. For aim two, number of treatments started per week in 2020 was compared with 2018/2019. Results: We selected 34,097 women for aim one. Compared to 2018/2019, neo-adjuvant chemotherapy was less likely for stage I (OR 0.24, 95%CI 0.11-0.53), stage II (OR 0.63, 95%CI 0.47-0.86), and hormone receptor+/HER2- tumors (OR 0.55, 95%CI 0.41-0.75) diagnosed during transition. Time between diagnosis and first treatment decreased for patients diagnosed during lockdown with a stage I (p < 0.01), II (p < 0.01) or III tumor (p = 0.01). We selected 30,002 women for aim two. The number of neo-adjuvant endocrine therapies and surgeries starting in week 14, 2020, increased by 339% and 18%, respectively. The number of adjuvant chemotherapies decreased by 42% in week 15 and increased by 44% in week 22. Conclusion: The pandemic and subsequently altered treatment recommendations affected multiple aspects of the breast cancer treatment strategy and the number of treatments started per week. (© 2022. The Author(s).) |
| References: | Ann Surg Oncol. 2021 Oct;28(10):5535-5543. (PMID: 34431019) Clin Oncol (R Coll Radiol). 2020 May;32(5):279-281. (PMID: 32241520) N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945) Breast Cancer Res Treat. 2021 May;187(1):187-196. (PMID: 33389397) Healthcare (Basel). 2020 Nov 11;8(4):. (PMID: 33187343) NPJ Breast Cancer. 2020 Jun 8;6:21. (PMID: 32550266) Breast Cancer Res Treat. 2020 Jun;181(3):487-497. (PMID: 32333293) Lancet Oncol. 2021 Mar;22(3):309-320. (PMID: 33493433) Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005002. (PMID: 17443564) Br J Cancer. 2021 May;124(11):1785-1794. (PMID: 33767422) J Hematol Oncol. 2021 Apr 17;14(1):64. (PMID: 33865430) Breast Cancer Res Treat. 2021 Apr;186(2):519-525. (PMID: 33146785) Br J Cancer. 2021 Apr;124(8):1353-1356. (PMID: 33526866) Lancet. 2020 Jun 20;395(10241):1919-1926. (PMID: 32473682) Clin Breast Cancer. 2020 Dec;20(6):454-461. (PMID: 32888855) Anticancer Res. 2020 Dec;40(12):7119-7125. (PMID: 33288611) Eur J Cancer. 2015 Aug;51(12):1497-510. (PMID: 26025767) JCO Oncol Pract. 2021 Sep;17(9):534-540. (PMID: 33710914) Breast Cancer Res Treat. 2022 Feb;191(3):665-675. (PMID: 34988767) Lancet Oncol. 2020 Jun;21(6):750-751. (PMID: 32359403) Ned Tijdschr Geneeskd. 2020 Jul 16;164:. (PMID: 32779917) Lancet Oncol. 2021 Jan;22(1):66-73. (PMID: 33253639) ESMO Open. 2020 May;5(Suppl 3):. (PMID: 32439716) |
| معلومات مُعتمدة: | 10430022010014 Netherlands ZONMW_ ZonMw |
| فهرسة مساهمة: | Investigator: JC van Hoeve; MAW Merkx; NJ de Wit; I Dingemans; ID Nagtegaal Keywords: Breast cancer; Breast cancer care; COVID-19; Treatment |
| تواريخ الأحداث: | Date Created: 20221105 Date Completed: 20230110 Latest Revision: 20230111 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9638417 |
| DOI: | 10.1007/s10549-022-06732-y |
| PMID: | 36334188 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1573-7217 |
|---|---|
| DOI: | 10.1007/s10549-022-06732-y |